Theodore Leonsis Sells 205,847 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Theodore Leonsis sold 205,847 shares of the firm’s stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $67.66, for a total transaction of $13,927,608.02. Following the completion of the transaction, the director now owns 15,511 shares of the company’s stock, valued at approximately $1,049,474.26. This trade represents a 92.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $71.22 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a market cap of $12.33 billion and a PE ratio of -9.13. The business has a 50 day moving average of $55.90 and a 200 day moving average of $52.39. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 6th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03. The business had revenue of $255.74 million for the quarter, compared to the consensus estimate of $248.13 million. The business’s revenue was up 75.4% compared to the same quarter last year. As a group, equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Institutional Investors Weigh In On Tempus AI

Large investors have recently bought and sold shares of the business. Operose Advisors LLC purchased a new position in Tempus AI in the fourth quarter worth about $25,000. Cherry Tree Wealth Management LLC bought a new stake in shares of Tempus AI during the first quarter valued at approximately $31,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Tempus AI during the first quarter valued at approximately $33,000. Farther Finance Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $34,000. Finally, Prestige Wealth Management Group LLC grew its holdings in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. BTIG Research started coverage on shares of Tempus AI in a research report on Monday, April 21st. They set a “buy” rating and a $60.00 price objective for the company. Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Morgan Stanley boosted their price objective on Tempus AI from $60.00 to $65.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. Finally, Bank of America boosted their target price on Tempus AI from $48.00 to $68.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 20th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $63.42.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.